IN THE UNITED STATES DESIGNATED/ELECTED OFFICE 10/590724

International Application No.

PCT/EP2005/000273

International Filing Date

January 13, 2005

Priority Date(s) Claimed

February 26, 2004

Applicant(s) (DO/EO/US)

Lars BURGSDORF et al.

Title: PYRIDINAMIDE DERIVATIVES AS KINASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

\boxtimes		der 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information colosure statement is filed:						
		within three months of the filing date of a national application other than a CPA under § 1.53(d);						
	\boxtimes	within three months of the actual filing date of the national phase of a PCT application; OR						
		before the mailing of a first substantive office action (including after filing of an RCE).						
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ed in 37 C.F.R. § 1.97(b), but before the mailing date of:						
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and						

		is acco	ompanied by: 10/590724
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a r	notice of allowance under 37 C.F.R. § 1.311;
	AND i	s filed	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Statem	ients Ur	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited I	Materia)	<u>ls</u>	
		ancesto	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form y the applicant; see 37 C.F.R. § 1.98(d).
	\boxtimes	_	of materials listed but not attached were cited in an international search dated May 10, 2005.
		Not rec	quired by 37 CFR § 1.98.
		Copies	of the materials listed are attached (except for the foregoing).

10/590724

Non-English Language References

nglish	Language References
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
\boxtimes	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document
	A = document defining the general state of the art
	O = non-written disclosure
	P = intercalated document
	T = document cited to understand the theory or principle underlying the invention
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
	D = cited in the application
	L = cited for another reason
	& = publication of member of same patent family
\boxtimes	Translation of other relevant information on foreign search report
	In the search report, "Seite" means page, "Seiten" means pages, "Verbindungender Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.

Other Information

Paym	nent of Fees Due (If Any):	
	A check for \$ covering the fee identified above	e is attached.
	Please charge to Deposit Account No. 13-3402 \$	for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3229

Date: August 25, 2006

AJZ:hlw

K:\Merck\3000 - 3999\3229\Information Disclosure Statement.doc

Please type a plus sign (+) inside this box	+
Please type a plus sign (*) maide this box	-

PTO/SB/08A (08-00)____

Under the Paperwork Reduction Act of 1995, no persons a Substitute for form 1449A/PTO						Complete if Known
					Application Number	Unassigned
	INFO	RMATIO	N DISCL	OSURE	Filing Date	August 25, 2006
	STAT	TEMENT!	BY APP	LICANT	First Named Inventor	Lars BURGSDORF et al.
					Group Art Unit	Unassigned
		(use as many s	heets as nec	essary)	Examiner Name	Unassigned
	Sheet	1	of	1	Attorney Docket Number	MERCK-3229

	U.S. PATENT DOCUMENTS								
Examiner Initials *	Cite No.1	U.S. Patent Docum	nent Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY				
	A1	2003/032656	A1	Paul Manley et al.	02-13-2003				
	A2	2004/2544185	A1	Schering AG	12-16-2004				
	А3	2004/198782	A1	Schering AG	10-07-2004				

FOREIGN PATENT DOCUMENTS								
			Foreign Patent Docu	ment		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Т ⁶
	B1	wo	02/090352	Α	Schering AG	11-14-2002		A2
	B2	wo	00/27819	Α	Schering AG	05-18-2000		А3
		1						

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.